🟢 Capricor Therapeutics is trading 21.62% up today after FDA extended deramiocel's decision deadline

Capricor Therapeutics is trading 21.62% up now at $8.27 after the FDA extended deramiocel’s decision deadline to November 22, 2026.

• The three-month reprieve gives regulators additional time to review newly submitted Duchenne muscular dystrophy data, reviving hopes for approval despite July’s unfavorable 9-3 advisory-panel vote.
• Shares remain highly volatile after rising 8.11% to $6.80 on August 24.